NovaBridge Biosciences (NBP) Accumulated Depreciation & Amortization (2021 - 2023)

NovaBridge Biosciences (NBP) has 3 years of Accumulated Depreciation & Amortization data on file, last reported at $5.1 billion in Q4 2023.

• Quarterly Accumulated Depreciation & Amortization fell 40.72% year-over-year to $5.1 billion in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $5.1 billion (down 40.72% YoY) and the FY2023 annual result came in at $3.4 million, down 99.96% from the prior year.
• Accumulated Depreciation & Amortization retreated to $5.1 billion in Q4 2023 per NBP's latest filing, from $8.5 billion in the prior quarter.
• Across five years, Accumulated Depreciation & Amortization topped out at $8.5 billion in Q4 2022 and bottomed at $5.1 billion in Q4 2023.
• The 3-year median for Accumulated Depreciation & Amortization is $7.1 billion (2021), against an average of $6.9 billion.
• The widest annual swing landed in 2022, when Accumulated Depreciation & Amortization increased 19.58%; it then slumped 40.72% in 2023.
• Tracing NBP's Accumulated Depreciation & Amortization over 3 years: stood at $7.1 billion in 2021, then advanced by 19.58% to $8.5 billion in 2022, then tumbled by 40.72% to $5.1 billion in 2023.
• Per Business Quant, the three latest NBP Accumulated Depreciation & Amortization figures stand at $5.1 billion (Q4 2023), $8.5 billion (Q4 2022), and $7.1 billion (Q4 2021).

Peer Comparison